Market News & Trends
Sharp Invests $20 Million in Autoinjector & Pen Assembly Lines to Meet Rising Demand for Injectables
Sharp Services, a leader in pharmaceutical packaging, clinical trial services & sterile manufacturing, has announced a $20 million investment in its autoinjector and pen assembly,…
Osivax Announces First Participant Vaccinated in Phase 2b Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate
Osivax recently announced the first participant has been vaccinated in its Phase 2b clinical trial (NCT05569239) evaluating OVX836, the company’s broad-spectrum influenza A vaccine candidate.…
Terumo Blood & Cell Technologies Supports Expanded Access to Rare Disease Therapies in Latin America
In a significant step toward expanding treatment access for people with rare and chronic diseases in Latin America (LATAM), Terumo Blood and Cell Technologies (Terumo…
Areteia Therapeutics Announces Positive Topline Results From First Phase 3 Study of Oral Dexpramipexole in Eosinophilic Asthma
Areteia Therapeutics, Inc. recently announced positive results from the Phase 3 EXHALE-4 efficacy and safety study of dexpramipexole as an add-on oral therapy in participants…
FORE Biotherapeutics Presents Phase 1/2a Plixorafenib Data Demonstrating Prolonged Duration of Effect in BRAF Altered Thyroid Cancers
FORE Biotherapeutics recently presented new plixorafenib results from the previously completed Phase 1/2a clinical trial that demonstrate treatment with plixorafenib in patients with BRAF-altered papillary…
Upperton Wins Pharma Contract Services Company of the Year at the Pharma Industry Awards UK 2025
Upperton Pharma Solutions has added another impressive award to a growing list of achievements, winning the award for Pharma Contract Services Company of the Year…
Monte Rosa Therapeutics Announces Collaboration With Novartis for Degraders to Treat Immune-Mediated Diseases
Monte Rosa Therapeutics, Inc. recently announced an agreement to collaborate with Novartis to develop novel degraders for immune-mediated diseases. The agreement is the company’s second…
Abzena Enhances AbZelectPRO Cell Line Offering With New GS Knockout Platforms
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its AbZelectPRO™ cell line development (CLD) platform with the launch…
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio
Cadrenal Therapeutics, Inc. recently announced the acquisition of the assets of eXIthera Pharmaceuticals, including its proprietary portfolio of investigational intravenous (IV) and oral Factor XIa…
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 Trial of the First Anti-TL1A Antibody Studied in Rheumatic Diseases
Spyre Therapeutics, Inc. recently announced the first patient has been dosed in its Phase 2 SKYWAY basket trial evaluating SPY072 in RA, PsA, and axSpA.…
Department of Defense Awards Grant to Advance Tiziana Life Sciences' Intranasal Anti-CD3 Therapy for Spinal Cord Injury
Tiziana Life Sciences, Ltd. recently announced that the US Department of Defense (DoD) has awarded a research grant to study the use of intranasal anti-CD3…
Belite Bio Announces Completion a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease
Belite Bio Inc. recently announced the completion of the last subject visit in the Phase 3 DRAGON clinical trial evaluating Tinlarebant for the treatment of Stargardt…
CPHI Frankfurt 2025 to Welcome More Than 60,000 Pharma Professionals as the Global Event Returns to Germany
Informa Markets will once again welcome the global pharmaceutical industry to CPHI Frankfurt 2025, running from October 28 to 30 at Messe Frankfurt. The three-day event…
Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach & Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration
Silexion Therapeutics Corp. recently announced new preclinical data demonstrating that subcutaneously administered SIL204 successfully reaches all primary sites of pancreatic cancer metastasis and shows anti-tumor…
Trethera Successfully Completes Enrollment of Phase 1 Dose Escalation Trial for Patients With Solid Tumors
Trethera Corporation recently announced the final patient has enrolled in its Phase 1 dose escalation trial for the treatment of advanced solid tumors. Patients have…
Symeres Acquires DGr Pharma to Enhance Regulatory Expertise & Broaden Biopharma Capabilities
Symeres recently announced the acquisition of DGr Pharma, a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for…
Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis
Karyopharm Therapeutics Inc. recently announced it has completed enrollment in the Phase 3 SENTRY trial, which is evaluating selinexor in combination with ruxolitinib in JAKi-naïve…
Biosplice Therapeutics Announces First Patient Dosed in NCI-Sponsored Clinical Trial of Cirtuvivint in AML & Myelodysplastic Syndromes
Biosplice Therapeutics, Inc. recently announced the first patient has been dosed in a Phase 1 clinical trial of cirtuvivint in patients with acute myeloid leukemia…
HCW Biologics Reports Positive Results From Non-Human Primate Study for its Proprietary Second-Generation T-Cell Engager Program
HCW Biologics Inc. recently announced its scientists have successfully developed second-generation, tissue factor-targeting T-cell engagers against solid tumors, particularly for pancreatic cancer and glioblastoma, constructed…
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients With Osteoarthritis
Enlivex Therapeutics Ltd. recently announced the issuance of an Israeli patent, numbered 290470, titled THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS. The patent will provide…
